TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04710290

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoglobuin
Description: Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch
Description: Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
Study: NCT03218813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention cohort ('after' group)
Description: The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').
Study: NCT01616550

Intervention type: OTHER
Intervention: Assessment of pain using the Brief Pain Questionnaire
Description: Patients will complete this questionnaire daily from surgery until discharge from the hospital

Intervention type: OTHER
Intervention: Assessment of pain relief using a Verbal Numeric Scale (VNS)
Description: Patients will assess their pain daily from surgery until discharge from the hospital using the VNS

Intervention type: OTHER
Intervention: Assessment of patient' satisfaction with pain relief
Description: Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)

Intervention type: OTHER
Intervention: Nurse's satisfaction with patient's pain relief and recovery
Description: Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
Study: NCT01347957

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
Study: NCT01762462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT03997734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB001
Description: single and repeated dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB001
Description: single and repeated dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral capsule
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: positive comparative patch
Description: single and repeated dosing
Study: NCT02714946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Ablation
Description: Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Radiofrequency Ablation
Description: Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
Study: NCT04170452

Intervention type: PROCEDURE
Intervention: liver biopsy
Description: Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
Study: NCT01418768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inpatient rehabiliation
Description: inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
Study: NCT00754767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate
Description: Given orally
Study: NCT02624297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The patients will be submitted to four months of aerobic exercise training, three time a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The patients will be submitted to four months of aerobic exercise training, three time a week.
Study: NCT02764853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (STEP-AD)
Description: This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Description: Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
Study: NCT00521911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Study: NCT01275547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-ketamine & midazolam
Description: s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA
Description: 2 mg Morphine i.v. all 12 minutes as a patient controlled system
Study: NCT04016584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Pueblo
Description: These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
Study: NCT00754767

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01570725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure
Description: The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music only
Description: A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
Study: NCT03103750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHNO
Description: Used as a tracer for in vivo imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHNO
Description: Used as a tracer for in vivo imaging.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: three 0.5 mcg capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: three 0.5 mcg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: three 0.5 mcg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: three 0.5 mcg capsules

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution research tomography
Description: A functional imaging technique that is used to observe metabolic processes in the body.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution research tomography
Description: A functional imaging technique that is used to observe metabolic processes in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextro Amphetamine
Description: Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextro Amphetamine
Description: Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
Study: NCT03531957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo of ASN002 for 12 weeks
Study: NCT02263339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise- Healthy Subjects
Description: Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
Study: NCT03780517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172738
Description: Oral capsules
Study: NCT02332915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment (SPT)
Description: SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment (SPT)
Description: SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
Study: NCT03927729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Pain will be treated with inhaled methoxyflurane (Penthrox®).
Study: NCT00576498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NBI-AFI imaging
Description: Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Endoscopy
Description: Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
Study: NCT01920139

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration and core biopsy of lymph node
Description: Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
Study: NCT00274781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
Study: NCT01028586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide, MAO-B inhibitor
Description: Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
Study: NCT01888887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Facial Cleanser
Study: NCT01992978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted Hepatectomy
Description: Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
Study: NCT01920139

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary surgery
Description: Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: Titanium marker
Description: A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
Study: NCT02675517

Intervention type: DRUG
Intervention: Spiolto Respimat
Description: Tiotropium bromide + Olodaterol
Study: NCT04012411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Punction
Description: Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Analysis of BDNF, Tau, NFL, and Val66Met polymorphism

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Analysis of BDNF, Tau, NFL, and Val66Met polymorphism

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive evaluation
Description: Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive evaluation
Description: Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
Study: NCT04165265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant-Care
Description: Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients
Study: NCT03000452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARATUMUMAB
Description: DARATUMUMAB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DURVALUMAB
Description: DURVALUMAB
Study: NCT03446170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic cigarette warning labels, plain packaging
Description: This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic cigarette warning labels, plain packaging
Description: This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic cigarette warning labels, plain packaging
Description: This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
Study: NCT01992978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hepatectomy
Description: Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
Study: NCT01028586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide, MAO-B inhibitor
Description: Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study: NCT01532635

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI given 6 days prior to transplant (HSCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is started the day before the transplant and stops a few months after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF is started the day before transplant and stops a few weeks after transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells.